Botanix Pharmaceuticals is a commercial-stage dermatology company developing novel treatments for serious skin conditions. Its lead product, Sofdra (sofpironium bromide gel, 12.45%), is the first FDA-approved new chemical entity for primary axillary hyperhidrosis.
Dermatology company Botanix Pharmaceuticals implemented a ~60% headcount reduction to cut FY27 operating expenses by approximately 50% while streamlining commercial operations around its FDA-approved hyperhidrosis treatment Sofdra.
Dermatology developer Botanix Pharmaceuticals announced a corporate restructuring cutting approximately 60% of its workforce and targeting a 50% reduction in FY27 operating expenses while focusing commercial capital on its FDA-approved hyperhidrosis gel Sofdra.
Chief Executive Officer
Executive Chairman
No active job listings. Check back later.